Vestal Point Capital’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$87.9M Sell
18,045,000
-1,370,000
-7% -$7.9M 2.27% 15
2026
Q2
$132M Buy
19,415,000
+1,415,000
+8% +$8.37M 3.09% 8
2026
Q1
$80.5M Buy
18,000,000
+4,250,000
+31% +$19.8M 2.25% 13
2025
Q4
$75.6M Buy
13,750,000
+8,250,000
+150% +$40.1M 2.57% 11
2025
Q3
$18M Buy
5,500,000
+2,500,000
+83% +$7.08M 0.81% 44
2025
Q2
$6.93M Buy
+3,000,000
New +$6.52M 0.36% 49

Other funds holding TSHA

Vestal Point Capital's TSHA Position: Q3 2026 in Review

Vestal Point Capital reduced its Taysha Gene Therapies (TSHA) stake by 7.1% in Q3 2026, selling an estimated $7.9M and leaving 18,045,000 shares worth $87.9M. The position accounts for 2.27% of the portfolio, ranked #15.

Vestal Point Capital first reported a position in TSHA in Q2 2025 and has held it in 6 quarters since. The position peaked at $132M in Q2 2026. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Vestal Point Capital held 18,045,000 shares of Taysha Gene Therapies worth $87.9M as of Q3 2026.
  • Vestal Point Capital sold 1,370,000 Taysha Gene Therapies shares in Q3 2026, an estimated $7.9M.
  • Taysha Gene Therapies made up 2.27% of Vestal Point Capital's portfolio in Q3 2026, its #15 holding.
  • Vestal Point Capital first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 6 quarters since.
  • Vestal Point Capital's Taysha Gene Therapies position peaked at $132M in Q2 2026.
  • 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Vestal Point Capital's 13F filing for Q3 2026, filed 16 Nov 2026.